Pathway for Softgel vs Tablet Comparison [Design Issues]

posted by Obinoscopy  – Nigeria, 2018-05-15 19:04  – Posting: # 18764
Views: 889

Dear bebac_fan,

» I think this would need to go through a NDA/505(b)(2) pathway rather than an ANDA.
»

I share the same view with you on this.

However I have a case where a BE study was conducted comparing Metronidazole tablet (Reference) with Metronidazole soft gel (test). Both were IR. Is this acceptable?

Regards,

Scopy

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,268 posts in 4,098 threads, 1,314 registered users;
online 12 (1 registered, 11 guests [including 7 identified bots]).

That which is not controversial
is of no particular interest.    Johann Wolfgang von Goethe

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5